Related Experiment Video

Updated: Apr 29, 2026

Quantitative Real-Time PCR Evaluation of microRNA Expressions in Mouse Kidney with Unilateral Ureteral Obstruction
07:36

Quantitative Real-Time PCR Evaluation of microRNA Expressions in Mouse Kidney with Unilateral Ureteral Obstruction

Published on: August 27, 2020

5.5K

Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy

Cheng-Hsu Chen1, Shih-Yin Chen2, Kuo-Hsiung Shu3

  • 1Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan ; Department of Internal Medicine, Chiayi Branch, Taichung Veterans General Hospital, Chiayi, Taiwan ; School of Medicine, China Medical University, Taichung, Taiwan ; Department of Life Science, Tunghai University, Taichung, Taiwan.

Biomed Research International
|May 14, 2014
PubMed

Insights

The urokinase plasminogen activator (uPA) gene 3'-UTR C/C genotype is linked to higher risks of end-stage renal disease (ESRD) and malignancies in patients with idiopathic membranous nephropathy (MN). This finding suggests careful treatment considerations for MN patients.

Area of Science:

  • Nephrology
  • Genetics
  • Oncology

Background:

  • Idiopathic membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults.
  • A significant percentage of MN patients develop end-stage renal disease (ESRD).
  • Urokinase plasminogen activator (uPA) is implicated in modulating renal fibrosis.

Purpose of the Study:

  • To investigate the association between uPA gene polymorphisms and the clinical outcomes of MN.
  • To explore the role of uPA gene variations in the development of ESRD and malignancies in MN patients.

Main Methods:

  • Genotyping of the uPA gene 3 étaire-UTR T/C polymorphism was conducted using polymerase chain reaction.
  • Study included 91 biopsy-diagnosed MN patients and 105 healthy controls.

Main Results:

  • The uPA gene 3 étaire-UTR T/C polymorphism genotype distribution did not influence the development of MN.
  • MN patients with the C/C genotype showed a higher incidence of acquired malignancies (15.9%) and progression to ESRD (20.7%).
  • No patients with the T/C genotype developed malignancies or progressed to ESRD within the study cohort.

Conclusions:

  • The uPA gene 3 étaire-UTR C/C genotype is significantly associated with an increased risk of ESRD and acquired malignancies in MN patients.
  • These genetic findings necessitate tailored treatment strategies for MN patients to balance disease management and cancer risk reduction.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

36.1K
Application of Laser Microdissection to Uncover Regional Transcriptomics in Human Kidney Tissue05:46

Application of Laser Microdissection to Uncover Regional Transcriptomics in Human Kidney Tissue

Published on: June 9, 2020

3.7K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
9.4K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K